AbstractBackgroundWhen and how to communicate effectively the results of genetic and biomarker based prediction, detection, and quantification of the brain substrates of dementia involve important ethical and legal issues critical for precision medicine. AGREEDementia is an open working group that focuses on informed discussions and development of educational material to support communication and use of this information.MethodMembers attend two meetings monthly via videoteleconference. One meeting is a targeted working group that focuses on the following: 1. People with Symptoms, 2. People without Symptoms, 3. Research, 4. Ethics/Healthcare Law, 5. Diversity. Members also attend a monthly “all hands” meeting where they receive updates from other groups, partner organizations, and hear presentations on emerging research and resources.ResultOver the past few years AGREEDementia has produced several collaborative papers, webinars, and decision tools for people considering undergoing biomarker testing that will be discussed. Membership continues to grow to over 120 though level of involvement varies. The group is largely comprised of academic researchers (76%) including neurologists, neuropsychologists, clinical trial coordinators, ethicists, and healthcare lawyers. The second largest subgroup was from advocacy groups and stakeholders (18%) and 6% are students. Collaborations with other organizations including the NIA, Alzheimer’s Association/ISTAART, the Lewy Body Dementia Association, Association for Frontotemporal Dementia, and Cohen Veterans Bioscience greatly enrich the group by publicizing conferences and collaborating on papers and products. The Alzheimer’s & Dementia Outreach, Recruitment & Engagement at NIA also disseminates decision tools and other materials. Over time, the stakeholder group developed from an audience providing consultation to a creative force that pioneered a program to support people with cognitive dysfunction attending AAIC and other scientific conferences. The Diversity workgroup was added in order to mentor and teach research staff in sensitive outreach to diverse cohorts. The ongoing, monthly, lecture series and links to all these materials are hosted at a website, AGREEDementia.com.ConclusionWith controversies around how best to integrate biomarker and genetic information into clinical care, when to share research data with the public, and implement novel biomarker‐based therapies, AGREEDementia has provided an open forum for all to visit and consult.